No Data
No Data
Citi Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $7
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $7
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
Express News | Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO
Express News | Applied Therapeutics Appoints John H. Johnson as Executive Chairman